Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine in Healthy Female Children

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by GlaxoSmithKline
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01627561
First received: June 14, 2012
Last updated: September 25, 2014
Last verified: August 2014
  Purpose

The current study will evaluate the immunogenicity and safety of Cervarix when administered according to a 2-dose schedule with or without co-administration of GSK Biologicals' MMR and DTPa vaccines in 4-6 years old female subjects as compared to the standard 3-dose schedule in 15-25 years old female subjects, the population in which the clinical efficacy has been demonstrated.


Condition Intervention Phase
Infections, Papillomavirus
Biological: Cervarix
Biological: MMR
Biological: DTPa
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • The occurrence of solicited local adverse events (AEs) in Groups HPV_2D and MMR_DTPa. [ Time Frame: During the 7-day period (Days 0-6) following each vaccination ] [ Designated as safety issue: No ]
  • The occurrence of solicited general AEs in Groups HPV_2D and MMR_DTPa. [ Time Frame: During the 7-day period (Days 0-6) following each vaccination ] [ Designated as safety issue: No ]
  • The occurrence of unsolicited AEs in Groups HPV_2D and MMR_DTPa. [ Time Frame: During the 43-day period (Days 0-42) following vaccination on Day 0 ] [ Designated as safety issue: No ]
  • Occurrence of unsolicited AEs in Groups HPV_2D and MMR_DTPa. [ Time Frame: During the 30-day period (Days 0-29) following vaccination at Month 6 ] [ Designated as safety issue: No ]
  • The occurrence of clinically relevant abnormalities in biochemical and haematological parameters in Groups HPV_2D and MMR_DTPa. [ Time Frame: At Day 42 post vaccination on Day 0 ] [ Designated as safety issue: No ]
  • Occurrence of clinically relevant abnormalities in biochemical and haematological parameters in Groups HPV_2D and MMR_DTPa. [ Time Frame: At Day 29 post vaccination at Month 6 ] [ Designated as safety issue: No ]
  • The occurrence of serious adverse events (SAEs) in Groups HPV_2D and MMR_DTPa. [ Time Frame: From first vaccination to one month after the last vaccine dose (from Day 0 up to Month 7) ] [ Designated as safety issue: No ]
  • The occurrence of AEs and SAEs leading to withdrawal in Groups HPV_2D and MMR_DTPa. [ Time Frame: From first vaccination to one month after the last vaccine dose (from Day 0 up to Month 7) ] [ Designated as safety issue: No ]
  • The occurrence of potential immune-mediated diseases (pIMDs) in Groups HPV_2D and MMR_DTPa. [ Time Frame: From first vaccination to one month after the last vaccine dose (from Day 0 up to Month 7) ] [ Designated as safety issue: No ]
  • The occurrence of medically significant conditions (MSCs) in Groups HPV_2D and MMR_DTPa. [ Time Frame: From first vaccination to one month after the last vaccine dose (from Day 0 up to Month 7) ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 seroconversion rates assessed by Enzyme-Linked Immunosorbent Assay (ELISA) in Groups HPV_2D and HPV_3D [ Time Frame: One month after the last dose of study vaccine (Month 7) ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 antibody titres assessed by ELISA in Groups HPV_2D and HPV_3D [ Time Frame: One month after the last dose of study vaccine (Month 7) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Anti-HPV-16/18 seroconversion rates assessed by ELISA in Group MMR_DTPa [ Time Frame: At Day 0, Month 7 and Month 12 ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 antibody titres assessed by ELISA in Group MMR_DTPa [ Time Frame: At Day 0, Month 7 and Month 12 ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 seroconversion rates assessed by ELISA in Groups HPV_2D, HPV_2D CO and HPV_3D. [ Time Frame: At Day 0 and Months 7, 12, 18, 24 and 36 ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 antibody titres assessed by ELISA in Groups HPV_2D, HPV_2D CO and HPV_3D. [ Time Frame: At Day 0 and Months 7, 12, 18, 24 and 36 ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 seroconversion rates assessed by Pseudovirion-Based Neutralization Assay (PBNA) in a sub-cohort in Group MMR_DTPa [ Time Frame: At Day 0, Month 7 and Month 12 ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 antibody titres assessed by PBNA in a sub-cohort in Group MMR_DTPa [ Time Frame: At Day 0, Month 7 and Month 12 ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 seroconversion rates assessed by PBNA in a sub-cohort in Groups HPV_2D, HPV_2D CO and HPV_3D. [ Time Frame: At Day 0 and Months 7, 12, 18, 24 and 36 ] [ Designated as safety issue: No ]
  • Anti-HPV-16/18 antibody titres assessed by PBNA in a sub-cohort in Groups HPV_2D, HPV_2D CO and HPV_3D. [ Time Frame: At Day 0 and Months 7, 12, 18, 24 and 36 ] [ Designated as safety issue: No ]
  • Anti-measles, mumps and rubella seropositivity rates in Groups HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: On Days 0 and 42 ] [ Designated as safety issue: No ]
  • Anti-measles, mumps and rubella antibody titres in Groups HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: On Days 0 and 42 ] [ Designated as safety issue: No ]
  • Vaccine response rates to filamentous haemagglutinin (FHA), pertactin (PRN) and pertussis toxoid (PT) antigens in Groups HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: At Month 7 ] [ Designated as safety issue: No ]
  • Seroprotection rates to diphtheria (D) and tetanus (T) antigens in Groups HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: At Month 7 ] [ Designated as safety issue: No ]
  • The occurrence of solicited local AEs in all groups. [ Time Frame: During the 7-day period (Days 0-6) following each vaccination ] [ Designated as safety issue: No ]
  • The occurrence of solicited general AEs in all groups. [ Time Frame: During the 7-day period (Days 0-6) following each vaccination ] [ Designated as safety issue: No ]
  • The occurrence of solicited fever, measles/rubella-like rash, parotid gland swelling and signs of meningism, including febrile convulsion, in Groups MMR_DTPa and HPV_2D CO. [ Time Frame: During the 43-day period (Days 0-42) following vaccination on Day 0 ] [ Designated as safety issue: No ]
  • The occurrence of unsolicited AEs in Groups HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: During the 43-day period (Days 0-42) following vaccination on Day 0 ] [ Designated as safety issue: No ]
  • The occurrence of unsolicited symptoms in Groups HPV_3D, HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: During the 30-day period (Days 0-29) following each vaccination (Group HPV_3D) and during the 30-day period (Days 0-29) following vaccination at Month 6 (Groups HPV_2D, MMR_DTPa and HPV_2D CO). ] [ Designated as safety issue: No ]
  • The occurrence of clinically relevant abnormalities in biochemical and haematological parameters in Groups HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: At Day 42 post vaccination on Day 0 ] [ Designated as safety issue: No ]
  • Occurrence of clinically relevant abnormalities in biochemical and haematological parameters in Groups HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: At Day 29 post vaccination at Month 6 ] [ Designated as safety issue: No ]
  • The occurrence of pIMDs in all groups. [ Time Frame: From first vaccination to 6 months after the last vaccine dose (from Day 0 up to Month 12) ] [ Designated as safety issue: No ]
  • The occurrence of MSCs in all groups. [ Time Frame: From first vaccination to 6 months after the last vaccine dose (from Day 0 up to Month 12) ] [ Designated as safety issue: No ]
  • The occurrence of SAEs in all groups. [ Time Frame: From first vaccination to 6 months after the last vaccine dose (from Day 0 up to Month 12) ] [ Designated as safety issue: No ]
  • The occurrence of SAEs related to the investigational products, to study participation, to GSK concomitant products or any fatal SAE in all groups. [ Time Frame: Throughout the study period (From Day 0 to Month 36) ] [ Designated as safety issue: No ]
  • The occurrence of AEs/SAEs leading to withdrawal in all groups. [ Time Frame: Throughout the study period (From Day 0 to Month 36) ] [ Designated as safety issue: No ]
  • The occurrence of pregnancy and pregnancy outcomes in Group HPV_3D. [ Time Frame: From first vaccination to 6 months after the last vaccine dose (from Day 0 up to Month 12) ] [ Designated as safety issue: No ]
  • Number of subjects reporting the intake of concomitant medication in Groups HPV_2D, MMR_DTPa and HPV_2D CO. [ Time Frame: During the 43-day period (Days 0-42) following vaccination on Day 0 ] [ Designated as safety issue: No ]
  • Number of subjects reporting the intake of concomitant medication in all groups. [ Time Frame: During the 30-day period (Days 0-29) following each vaccination (Group HPV_3D) and during the 30-day period (Days 0-29) following vaccination at Month 6 (Groups HPV_2D, MMR_DTPa and HPV_2D CO) ] [ Designated as safety issue: No ]
  • The percentage of subjects completing the vaccination schedule in all groups. [ Time Frame: From first vaccination to the last vaccine dose (from Day 0 up to Month 6) ] [ Designated as safety issue: No ]

Estimated Enrollment: 1000
Study Start Date: October 2012
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HPV_2D group
Subjects aged 4-6 years receiving 2 doses of HPV vaccine at Day 0 and Month 6
Biological: Cervarix
2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6 in the HPV_2D and HPV_2D CO Groups 3 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0, Month 1 and Month 6 in the HPV_3D Group
Experimental: MMR_DTPa group
Subjects aged 4-6 years receiving 1 dose of MMR vaccine at Day 0 and 1 dose of DTPa vaccine at Month 6
Biological: MMR
1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Day 0
Biological: DTPa
1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Month 6
Experimental: HPV_2D CO group
Subjects aged 4-6 years receiving 2 doses of HPV vaccine. The first will be co-administered with MMR vaccine (at Day 0) and the second will be co-administered with DTPa vaccine (at Month 6)
Biological: Cervarix
2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6 in the HPV_2D and HPV_2D CO Groups 3 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0, Month 1 and Month 6 in the HPV_3D Group
Biological: MMR
1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Day 0
Biological: DTPa
1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Month 6
Active Comparator: HPV_3D group
Subjects aged 15-25 years receiving 3 doses of HPV vaccine at Day 0, Month 1 and Month 6
Biological: Cervarix
2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6 in the HPV_2D and HPV_2D CO Groups 3 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0, Month 1 and Month 6 in the HPV_3D Group

Detailed Description:

The study will be conducted in a partially blinded manner:

  • The study will be single-blind for the HPV_2D and MMR_DTPa groups up to the Month 12 visit due to the difference in the visual appearance of the study vaccines. Between Month 12 and study conclusion (Month 36), the study will be open with respect to HPV_2D group.
  • The study will be open with respect to the HPV_2D CO group as subjects in this group will be receiving two vaccines co-administered at each scheduled vaccination visit.
  • The study will be open with respect to the HPV_3D group as subjects in this group will be receiving three injections.
  Eligibility

Ages Eligible for Study:   4 Years to 25 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All subjects in the 4-6 years age groups must satisfy ALL the following criteria at study entry:

  • Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.
  • A female between, and including, 4 and 6 years of age at the time of the first vaccination.
  • Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to enrolment in the study.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Subjects who received four doses of DTP vaccine (i.e., three doses in the first year of life and a fourth dose in the second year of life) according to the schedule applicable in the participating countries.
  • Subjects who received a first dose of MMR vaccine according to the schedule applicable in the participating countries.

All subjects in the 15-25 years age group must satisfy ALL the following criteria at study entry:

  • Subjects who the investigator believes can and will comply with the requirements of the protocol and subjects who the investigator believes that parent(s)/LAR(s) can and will comply with the requirements of the protocol.
  • A female between, and including, 15 and 25 years of age at the time of the first vaccination.
  • Written informed consent obtained from the subject prior to enrolment in the study. For subjects below the legal age of consent, written informed consent has to be obtained from the parent(s)/LAR(s) of the subject and, in addition, the subject should sign and personally date a written informed assent.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Female subjects of non-childbearing potential.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

For all groups:

  • Child in care.
  • Previous vaccination against HPV or planned administration of another HPV vaccine during the study other than that foreseen in the protocol.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine(s). Administration of routine meningococcal, hepatitis B, hepatitis A, inactivated influenza and/or poliomyelitis vaccines up to 8 days before the first dose of study vaccine(s) is allowed. Enrolment will be deferred until the subject is outside of specified window.
  • Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine(s), or planned use during the study period.
  • History of any reactions or hypersensitivity likely to be exacerbated by any component of the study vaccines, including latex and/or obvious allergic reactions to neomycin, egg protein, etc.
  • Cancer or autoimmune disease under treatment.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous administration of MPL or AS04 adjuvant.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine(s) or planned administration during the study period.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Family history of congenital or hereditary immunodeficiency.
  • Documented human immunodeficiency virus (HIV)-positive subject.
  • Major congenital defects or serious chronic illness.
  • History of seizures or serious neurological disorder, which, according to the judgment of the investigator, precludes administration of any of the study vaccines.
  • Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, which in the opinion of the investigator precludes administration of the study vaccine(s).
  • Acute disease and/or fever at the time of enrolment.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose(s).

Additional exclusion criteria for subjects in the 4-6 years age groups only:

  • Previous administration of the fifth dose of DTP vaccine and/or the second dose of MMR vaccine or planned administration of DTP vaccine and/or MMR vaccine outside the study.
  • History of tetanus, diphtheria, pertussis, measles, mumps and/or rubella.
  • Known exposure to diphtheria or household exposure to pertussis within 30 days prior to vaccination with DTPa.
  • Known exposure to measles, mumps and/or rubella 30 days prior to vaccination with the MMR study vaccine.
  • Confirmed or suspected tuberculosis.
  • Severe allergic reactions following the administration of previous dose(s) of DTP or MMR vaccines.
  • Hyperpyrexia (≥ 40.5°C) within 48 hours of administration of previous doses of DTP or MMR vaccines.
  • Persistent, inconsolable crying lasting more than 3 hours, occurring within 48 hours of administration of previous doses of DTP vaccine.
  • Collapse or shocking-like state within 48 hours of administration of previous doses of DTP vaccine.
  • Idiopathic thrombocytopenic purpura or bleeding disorders.
  • Additional exclusion criteria for subjects in the 15-25 years age group only: Pregnant or breastfeeding.
  • A woman planning to become pregnant, likely to become pregnant or planning to discontinue contraceptive precautions during the vaccination phase of the study, i.e. up to two months after the last vaccine dose.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01627561

Contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com

Locations
Colombia
GSK Investigational Site Recruiting
Bogota, Colombia, 38007
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
GSK Investigational Site Recruiting
Yopal, Casanare, Colombia
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Mexico
GSK Investigational Site Recruiting
Mexico, Mexico, 04530
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
Panama
GSK Investigational Site Recruiting
Panama, Panamá, Panama
Contact: US GSK Clinical Trials Call Center    877-379-3718    GSKClinicalSupportHD@gsk.com   
Contact: EU GSK Clinical Trials Call Center    +44 (0) 20 8990 4466    GSKClinicalSupportHD@gsk.com   
GSK Investigational Site Terminated
Panama, Panama
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01627561     History of Changes
Other Study ID Numbers: 115887, 2011-005604-15
Study First Received: June 14, 2012
Last Updated: September 25, 2014
Health Authority: Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)

Keywords provided by GlaxoSmithKline:
Immune response
Human papillomavirus
HPV vaccine
Safety

ClinicalTrials.gov processed this record on October 19, 2014